Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 3
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages.
Murgaski A, Kiss M, Van Damme H, Kancheva D, Vanmeerbeek I, Keirsse J, Hadadi E, Brughmans J, Arnouk SM, Hamouda AEI, Debraekeleer A, Bosteels V, Elkrim Y, Boon L, Hoves S, Vandamme N, Deschoemaeker S, Janssens S, Garg AD, Vande Velde G, Schmittnaegel M, Ries CH, Laoui D. Murgaski A, et al. Among authors: arnouk sm. Cancer Res. 2022 Oct 17;82(20):3785-3801. doi: 10.1158/0008-5472.CAN-22-0094. Cancer Res. 2022. PMID: 35979635 Free PMC article.
Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting.
Erreni M, D'Autilia F, Avigni R, Bolli E, Arnouk SM, Movahedi K, Debie P, Anselmo A, Parente R, Vincke C, van Leeuwen FWB, Allavena P, Garlanda C, Mantovani A, Doni A, Hernot S, Van Ginderachter JA. Erreni M, et al. Among authors: arnouk sm. Theranostics. 2023 Jan 1;13(1):355-373. doi: 10.7150/thno.77560. eCollection 2023. Theranostics. 2023. PMID: 36593955 Free PMC article.
Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies.
Bolli E, Scherger M, Arnouk SM, Pombo Antunes AR, Straßburger D, Urschbach M, Stickdorn J, De Vlaminck K, Movahedi K, Räder HJ, Hernot S, Besenius P, Van Ginderachter JA, Nuhn L. Bolli E, et al. Among authors: arnouk sm. Adv Sci (Weinh). 2021 Mar 8;8(10):2004574. doi: 10.1002/advs.202004574. eCollection 2021 May. Adv Sci (Weinh). 2021. PMID: 34026453 Free PMC article.
Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors.
Bolli E, D'Huyvetter M, Murgaski A, Berus D, Stangé G, Clappaert EJ, Arnouk S, Pombo Antunes AR, Krasniqi A, Lahoutte T, Gonçalves A, Vuylsteke M, Raes G, Devoogdt N, Movahedi K, Van Ginderachter JA. Bolli E, et al. Among authors: arnouk s. J Control Release. 2019 Nov 28;314:1-11. doi: 10.1016/j.jconrel.2019.10.024. Epub 2019 Oct 15. J Control Release. 2019. PMID: 31626860
Junctional adhesion molecule-A is dispensable for myeloid cell recruitment and diversification in the tumor microenvironment.
Kiss M, Lebegge E, Murgaski A, Van Damme H, Kancheva D, Brughmans J, Scheyltjens I, Talebi A, Awad RM, Elkrim Y, Bardet PMR, Arnouk SM, Goyvaerts C, Swinnen J, Nana FA, Van Ginderachter JA, Laoui D. Kiss M, et al. Among authors: arnouk sm. Front Immunol. 2022 Dec 1;13:1003975. doi: 10.3389/fimmu.2022.1003975. eCollection 2022. Front Immunol. 2022. PMID: 36531986 Free PMC article.
IL1β Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D.
Kiss M, Vande Walle L, Saavedra PHV, Lebegge E, Van Damme H, Murgaski A, Qian J, Ehling M, Pretto S, Bolli E, Keirsse J, Bardet PMR, Arnouk SM, Elkrim Y, Schmoetten M, Brughmans J, Debraekeleer A, Fossoul A, Boon L, Raes G, van Loo G, Lambrechts D, Mazzone M, Beschin A, Wullaert A, Lamkanfi M, Van Ginderachter JA, Laoui D. Kiss M, et al. Among authors: arnouk sm. Cancer Immunol Res. 2021 Mar;9(3):309-323. doi: 10.1158/2326-6066.CIR-20-0431. Epub 2020 Dec 23. Cancer Immunol Res. 2021. PMID: 33361087